-+ 0.00%
-+ 0.00%
-+ 0.00%

Kangenbei (600572.SH) subsidiary's application for a new indication clinical trial of Musk Tongxin drip pills was approved

Zhitongcaijing·07/24/2026 08:25:01
Listen to the news

Zhitong Finance App News, Kangenbei (600572.SH) issued an announcement. Recently, Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. (“Inner Mongolia Kangenbei”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration regarding the new indications of Musk Tongxin Drop Pills. The new indication for this application is heart failure with preserved ejection scores (dialectical gas ischemia and blood stasis in traditional Chinese medicine), and the route of administration is oral administration.

According to reports, Zhixin ® Musk Tongxin Drops is a proprietary Chinese medicine independently developed and produced by Kangenbei, Inner Mongolia. It was approved and marketed in 2008. It is used for coronary artery disease-stabilizing stasis and pain relief. It is used for coronary artery disease-stabilizing stasis. Traditional Chinese medicine diagnoses gas ischemia and stasis. Symptoms include chest pain, chest tightness, shortness of breath, and fatigue.